Peptides for Weight Loss: What the Research on GLP-1 Agonists Actually Shows

GLP-1 receptor agonists dominate the peptide research landscape right now. Semaglutide, tirzepatide, and retatrutide have each generated landmark clinical data on body weight reduction — and the published results keep getting more dramatic with each generation of compound. This article breaks down what the peer-reviewed literature actually says, how the three compounds differ mechanistically, and where the research is headed.

The GLP-1 Mechanism: Why These Peptides Reduce Body Weight

Glucagon-like peptide-1 is a naturally occurring incretin hormone. GLP-1 receptor agonists mimic this hormone, binding to receptors in the hypothalamus that regulate appetite signaling. Published research identifies three primary downstream effects:

• Reduced appetite signaling — hypothalamic GLP-1R activation suppresses hunger drive at the neurological level
• Delayed gastric emptying — extends post-meal satiety by slowing digestive transit
• Improved insulin sensitivity — pancreatic beta-cell modulation enhances glucose homeostasis

These mechanisms have been established through decades of incretin biology research, beginning with the discovery of GLP-1’s role in glucose homeostasis in the 1980s and culminating in the large-scale clinical trials of the 2020s.

Semaglutide — The Clinical Benchmark

Semaglutide is a GLP-1 receptor agonist with a ~7-day half-life, enabling once-weekly administration in clinical study designs.

Semaglutide’s long duration of action and extensive published safety dataset make it the reference compound against which newer GLP-1 agonists are benchmarked.

Tirzepatide — Dual Agonism, Larger Effect Size

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — the first dual incretin agonist with large-scale published data.

Retatrutide — Triple Agonism and Phase 3 Data

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism — the first triple incretin agonist in advanced clinical development.

The glucagon receptor component is notable because glucagon stimulates hepatic energy expenditure and fatty acid oxidation — addressing the energy output side of the equation rather than just appetite suppression. Early published data suggests particularly strong effects on hepatic fat reduction, with implications for NAFLD/NASH research.

Head-to-Head: What the Literature Shows

Each successive generation has produced incrementally larger effect sizes in published trials:

However, direct head-to-head comparison data remains limited, and individual response variability is substantial across all three compounds. Side effect profiles — predominantly GI-related (nausea, diarrhea, constipation) during dose titration — are broadly similar across the class.

Other Peptides in Body Composition Research

Beyond GLP-1 agonists, published research has examined several other peptides in the context of body composition:

• MOTS-c — mitochondrial-derived peptide studied for AMPK-mediated metabolic effects and exercise-mimetic properties
• GH secretagogues (CJC-1295, Ipamorelin) — studied for effects on lean mass preservation during weight loss
• Tesamorelin — GHRH analog with published data specifically on selective visceral adipose tissue reduction